TJM Labs adds John M. Connolly to board

TJM Labs appointed veteran technology executive John M. Connolly as an independent board member as the pharmacy AI company continues to scale. The move adds leadership experience in executive development, go-to-market strategy and growth-stage operations as TJM Labs expands across the pharmacy industry.

Why it matters: - TJM Labs is adding a seasoned growth-stage operator as it tries to turn rapid expansion into a durable long-term advantage. - Connolly’s background in scaling technology companies could help shape the company’s organization, leadership bench and go-to-market execution. - The appointment comes as pharmacy providers face pressure to increase capacity without adding headcount.

What happened: - TJM Labs appointed John M. Connolly as an independent member of its Board of Directors. - The announcement came Aug. 27, 2026. - Connolly brings 30 years of experience as a CEO, founder, investor and board director. - TJM Labs said Connolly joins as the company enters its next stage of growth after expanding across the pharmacy industry.

The details: - Connolly will work with Founder and CEO Jonathan Adly and TJM Labs’ leadership team on organizational and strategic decisions tied to scale. - His focus areas include organizational design, executive development, go-to-market strategy and converting growth into long-term advantage. - Adly said Connolly has served as a five-time CEO, a two-time founder and a board director for companies including Fleetio, Limble and A Cloud Guru. - Connolly has served as chairman, non-executive chairman or director on more than 50 boards. - Connolly is founder and managing director of Eaglehead Capital and a lead advisor to Goldman Sachs Growth. - His advisory work has covered executive management, organizational development, market segmentation, capital strategy, talent development, acquisition and leadership development. - His board experience includes high-growth technology companies such as Fleetio, Limble, DebtBook and A Cloud Guru. - Connolly said TJM Labs has built a strong position at the intersection of AI and pharmacy and sees a large opportunity ahead.

Between the lines: - The board addition signals TJM Labs is shifting from product-led growth toward more formal scaling discipline. - The company appears to be reinforcing leadership capacity around hiring, structure and sales execution ahead of further expansion. - Connolly’s experience suggests TJM Labs is prioritizing operational maturity alongside product adoption.

What's next: - TJM Labs and Connolly are expected to work on scaling the business, strengthening executive development and refining market strategy. - The company will likely keep leaning on its automation platform as it expands pharmacy adoption. - TJM Labs also points to continued momentum from its broader platform strategy and prior acquisitions.

The bottom line: - TJM Labs is betting that proven growth-stage governance can help its pharmacy AI business scale faster and more sustainably.